This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: star one on your telephone. To withdraw your question, press the pound key. Our next question comes from the line of John Krieger from William Blair. Your line is now open.
spk01: Hey, thanks, guys. I have a couple of questions about mix. I think in the past you've talked about your revenue mix being mainly in clinical with much smaller chunks in discovery, preclinical, and postmarket. assuming I've got that right, if you look at your recent bookings, are you seeing any shift in that mix, or should we expect that to be fairly typical? What I'm getting at is sort of where are you seeing the biggest changes in how clients are using your software?
spk03: Andrew, do you want to address that first?
spk02: Sure, I can start. The mix is consistent with the previously discussed mix, so no changes there.
spk01: Great. Thanks, Andrew. And maybe a similar one, how about mix between large and small clients? Is that fairly stable, or are you seeing any change?
spk02: I can answer that. What we're seeing is growth in both areas. We're seeing growth in more of the mid-teens. in large clients and higher growth rates and uptake with the small clients. We had a record number of new logos in the first quarter.
spk01: All right, thanks. And then maybe one more. Bill, can you just talk a little bit about how you guys have played a role in COVID work? Should we view that as at all a material contributor if you think back to the last couple of quarters and, therefore, would you expect it to be a headwind or a tailwind as you move through 2021?
spk03: Yeah, thanks, John. The way I think about this is the business was really resilient throughout COVID, so I'm really proud that we were able to continue serving our clients without really skipping a beat. We did work on, I forget what we said last year, you know, more than 30 COVID projects last year. But, you know... a lot of that had to do with the customers moved to work on COVID and we moved with them. And then when they moved back to work on other things, we're moving back with them. So from a financial standpoint, you know, we don't believe this, that, that, that, that it will really be a, you know, a significant event. Um, obviously the operations of the company, we, we, we did, you know, we worked on somewhat different projects last year. Uh, and you know, we're, we're managing, um, you know, the disruptions that to some extent happen in the pharmaceutical pipeline as we go into the first quarter. But, you know, we have a very diverse and broad business across pharma. And so that kind of lets it basically makes us, you know, pretty stable throughout the whole thing. So I wouldn't expect it to be either really a headwind or a tailwind as we go into this year.
spk01: Okay, thank you.
spk04: Thank you. At this time, I'm showing no further questions. I would like to turn the call back over to William Thierry, CEO, for closing remarks.
spk03: I wanted to thank everybody for joining us. This was our first quarter as a public company. I believe that Certara performed very well. I'm very proud of our team. The team set out with a very good, solid plan. I believe we've delivered on that throughout the quarter, and I think we are quite well set up as we go forward for the rest of the year. We'll look forward to updating everybody in the coming quarters. Thank you very much, and with that, I think we can wrap up tonight. Thank you.
spk04: This concludes today's conference call. Thanks for participating. You may now disconnect.
Disclaimer